Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INS018_055 in idiopathic pulmonary fibrosis
NCT05938920Phase 2Completed
- Sponsor
- Insilico Medicine
- Start
- Jun 2023
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of INS018_055 in idiopathic pulmonary fibrosis (IPF), sponsored by Insilico Medicine. Started Jun 2023; status: completed.
02
Drugs
INS018_055
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05938920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05938920.